Methodological and regulatory aspects of pharmaceutical development of biological products
Authors:
- D. V. KurkinDKD. V. Kurkin
- E. I. MorkovinEME. I. Morkovin
- D. A. BakulinDBD. A. Bakulin
- А. В. ЗаборовскийАЗА. В. Заборовский
- I. E. MakarenkoIMI. E. Makarenko
- R. V. DraiRDR. V. Drai
- A. G. SolodovnikovASA. G. Solodovnikov
- V. I. PetrovVPV. I. Petrov
- K. N. KoryanovaKKK. N. Koryanova
- N. A. LychevaNLN. A. Lycheva
- С. А. ВоскресенскийСВС. А. Воскресенский
- A. V. StryginASA. V. Strygin
Open Access
- 29 January 2024
- journal article
- review article
- Published by Volgograd State Medical University in Pharmacy & Pharmacology
- Vol. 11 (5) , 384-398-398
Abstract
The aim of the work was to conduct an analysis of the current state and current trends in the approval of drugs, as well as some aspects of the methodology for their development based on biological molecules and registration.Materials and methods. The material for the analysis was taken from the abstract databases of PubMed, Google Scholar and e-library.ru. The search was carried out using publications for the period from 2008 to 2023, the keywords were as follows: “biologicals”, “new drug approval”, “drug authorization”, “drug development”, “biosimilar”, taking into account various spellings.Results. Over the past 15 years, scientists have been observing revolutionary trends and processes in the field of the drug development, especially biopharmaceuticals. Significant advances have been made in gene, immune and cell therapies, resulting in the approval of such drugs more than doubling over the past ten years. The development of biological drugs includes the identification and testing of molecular targets and requires a deep understanding of the structure and functioning of the polypeptides involved in the development of the effect. The features of these active pharmaceutical substances are a high molecular weight, a complex three-dimensional structure and a high immunogenic potential. Preclinical and clinical studies of biologics have unique challenges. Selecting appropriate animal species, understanding the immunogenicity, and assessing pharmacodynamics and toxicological properties require a multilevel, detailed approach. The article discusses the regulatory framework under which these drugs are registered, summarizing the guidelines provided by international organizations such as the International Council for Harmonization and various national agencies.Conclusion. The analysis highlights the current advances and prospects in the development of biologics, highlighting their key role in future transformations in the treatment of rare diseases and oncology, approaching the era of personalized medicine. Monitoring the development directions and technological approaches, as well as the commitment to global methodological and regulatory aspects can become a catalyst in the development of the Russian pharmacology.Keywords
This publication has 50 references indexed in Scilit:
- An Overview of Drug Discovery and DevelopmentFuture Medicinal Chemistry, 2020
- Barriers to Ensuring Access to Affordable Prescription DrugsAnnual Review of Pharmacology and Toxicology, 2020
- Top 10 Challenges in Cancer ImmunotherapyImmunity, 2020
- Bioactive Compounds and Pharmaceutical Excipients Derived from Animals, Marine Organisms, Microorganisms, Minerals, Synthesized Compounds, and Pharmaceutical Drugs2018
- TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse ModelPLOS ONE, 2016
- Properties of Protein Drug Target ClassesPLOS ONE, 2015
- In Vivo Target Validation Using Biological Molecules in Drug Development2015
- Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T‐cellsBritish Journal of Pharmacology, 2010
- TGN1412: From Discovery to DisasterJournal of Young Pharmacists, 2010
- Species selection considerations for preclinical toxicology studies for biotherapeuticsExpert Opinion on Drug Metabolism & Toxicology, 2008